Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men

Phase 1
Completed
Conditions
Interventions
First Posted Date
2024-07-10
Last Posted Date
2024-12-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT06494774
Locations
🇯🇵

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2024-07-09
Last Posted Date
2024-11-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
60
Registration Number
NCT06492135
Locations
🇨🇳

Shanghai Central Hospital of Xuhui District, Shanghai, China

Real-life-persistence to Antifibrotic Treatments

Active, not recruiting
Conditions
Interventions
First Posted Date
2024-07-03
Last Posted Date
2024-11-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
800
Registration Number
NCT06485635
Locations
🇫🇷

Clinityx, Boulogne-Billancourt, France

A Study in Healthy People to Compare Two Different Sifrol® Tablets

First Posted Date
2024-06-13
Last Posted Date
2024-08-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
28
Registration Number
NCT06457204
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-05-24
Last Posted Date
2024-12-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
64
Registration Number
NCT06429137
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2024-05-22
Last Posted Date
2024-12-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6000
Registration Number
NCT06424288
Locations
🇺🇸

Butler Health System Cardiovascular Consultants, Butler, Pennsylvania, United States

🇺🇸

Sentara Norfolk General Hospital, Norfolk, Virginia, United States

🇺🇸

University of California Irvine, Orange, California, United States

and more 14 locations

A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood

Phase 1
Completed
Conditions
Interventions
First Posted Date
2024-05-17
Last Posted Date
2024-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT06419660
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

Phase 1
Completed
Conditions
Interventions
First Posted Date
2024-05-16
Last Posted Date
2024-07-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT06415045
Locations
🇩🇪

CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2024-05-10
Last Posted Date
2024-08-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
64
Registration Number
NCT06408870
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

First Posted Date
2024-05-01
Last Posted Date
2024-12-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
64
Registration Number
NCT06393127
Locations
🇩🇪

Charité Research Organisation GmbH, Berlin, Germany

© Copyright 2024. All Rights Reserved by MedPath